Default company panoramic image
Db22e4e7 a794 468d a052 d82e094b02c1

SPI Acquisition Corp.

Soluprin has created technology that relates to a Novel Soluble Aspirin formulation for pain management that is non-sedative.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Merrick, NY, USA
  • Currency USD
  • Founded April 2010
  • Employees 26
  • Website

Company Summary

New York development stage research and development company specializing in medical research to address the pain management market with specific expertise in a new understanding of the mechanism of action for a new form of fast acting powerful soluble Aspirin. The purpose of the company is to acquire technology in the field of pain management to complement its core soluble Aspirin compound and commercialize the sale of the product.


  • Default avatar
    Donald A Milne III

    Accomplishments in the field of medical research and drug development financing. recruited in 2002 to Washington D.C. to help accelerate the R&D in bio metric security and passenger reconciliation in US airports. Milne currently hold 16 patents. founder and Chief Operating Officer of InteliTrac, Inc. Milne financed many ventures including Perfumania, Myriad Genetics, Medarex and Genentech. Milne helped with a capital raise for Amgen.

  • Default avatar
    Douglas A Horne
    Business Advisory Committee

    Horne has over fifteen years of experience in corporate finance, communications, government relations, and public affairs. His experience mergers, acquisitions and divestitures, including reverse take-overs. During his term with CMLF assets under management increased from $30 Million to $400 Million. More recently, a founder and President of Advanced Strategies Inc. A corporate finance advisory group for micro and small-capitalized companies.

  • Default avatar
    Dr. Kennith Sun
    Scientific Advisory Board

    Dr. Sun currently serves as a member of the Advisory Board. Dr. Sun has, since December 1998, served as the President and Chief Executive Officer of E-View Inc. an Internet technology and service company and as Chief Executive Officer of Genova Pharmaceuticals, Inc. co-author of three United States patents relating to gene screening. authored more than thirty scientific papers in the areas of protein chemistry, drug design and applied physics.

  • Default avatar
    Dr. John N. Vournakis
    Scientific Advisory Board

    Vice President for Research and Development at Marine Polymer Technologies, Inc. In Burlington, MA. Professor of Graduate Studies at the Medical University of South Carolina. Dartmouth College as Professor of Biology, 1984 – 1995. received a PhD degree from Cornell University, Department of Physical Biochemistry in 1968. Post-Doctoral at MIT and Harvard University in the fields of Molecular Biology and Genetics between 1969 and 1973.


  • Default avatar
    Snow, Becker, Krauss, P.C.
    Default avatar
    JDC & Associates, Inc.